Provided is an apparatus for measuring the thickness, roughness, and morphology index of the mandibular cortical bone using a dental panorama image to assist in the diagnosis of osteoporosis, wherein the thickness, roughness, and morphological index of the cortical bone is measured more accurately and the diagnosis of osteoporosis can be supported more accurately. An osteoporosis diagnostic support apparatus, wherein the apparatus has a contour extraction unit adapted to extract a mandibular contour from an image of a mandibular cortical bone photographed by a photographic apparatus adapted to photograph the mandibular cortical bone and surroundings thereof, a line segment extraction unit adapted to extract line segments from the image of the mandibular cortical bone photographed by the photographic apparatus; and a cortical bone thickness calculation unit adapted to calculate a thickness of the cortical bone based on the extracted mandibular contour and line segments.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
The invention provides methods and compositions for treating cancer by administering to a patient in need thereof a therapeutically effective amount of 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
To provide a secondary battery enabling quick charging, and a method for suitable use of the secondary battery. A secondary battery system 1 comprises a hydrogen source 10 including a hydrogen production device. A secondary battery 11 comprises: a positive electrode 12; a negative electrode 13 containing a hydrogen absorbing alloy; a separator 14; and a container 15 accommodating the positive electrode 12, the negative electrode 14, and the separator 13. The secondary battery system of the present invention further comprises a hydrogen flow path 21 that connects the secondary battery 11 to the hydrogen source 10 so as to introduce hydrogen to the secondary battery 11 and to discharge excess hydrogen therefrom. In the secondary battery system 1 of the present invention, discharging and quick charging can be repeated by the step of supplying hydrogen from the hydrogen source 10 to the negative electrode 13, the step of discharging to supply electricity to an external load, the step of charging to supply a given current from an external power supply 30 to the positive electrode 12 and the negative electrode 13, and the step of discharging hydrogen that is a by-product of the charging step to the hydrogen flow path 21.
The present invention addresses the issue of providing a recombinant phage that is highly safe and has excellent practicality and usefulness. Provided are: a recombinant bacteriophage that has lost proliferative capacity and can only infect once, as a result of having a bacteriophage genome having part of a virion-constituting gene deleted therefrom stored in the head thereof; and a preparation method therefor. Also provided are: a recombinant bacteriophage that has lost proliferative capacity and can only infect once, as a result of having a plasmid having a packaging site and coding a target gene stored in the head thereof; and a preparation method therefor.
The invention provides methods and compositions for treating cancer by administering to a patient in need thereof a therapeutically effective amount of 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A method for producing a separation membrane where a zeolite film is formed on an inorganic oxide porous supporting body, said method comprising: a surface layer formation step wherein a surface layer containing 90% by weight or more of silica is formed on at least one of the surface of the supporting body and the inside of the supporting body in the vicinity of the surface of the supporting body; a loading step wherein the surface and/or the inside of the surface layer is loaded with a seed crystal of zeolite and a component that contains a structure directing agent; and a steam treatment step wherein the member obtained in the loading step is subjected to a treatment in a heated steam atmosphere.
C01B 39/04 - Zéolites aluminosilicates cristallinesLeurs composés isomorphesLeur préparation directeLeur préparation à partir d'un mélange réactionnel contenant une zéolite cristalline d'un autre type, ou à partir de réactants préformésLeur post-traitement utilisant au moins un agent structurant organique, p. ex. un composé d'ammonium quaternaire ionique ou un composé aminé
[Problem] To provide an electromagnetic wave measurement probe capable of measuring a spatial distribution state of electromagnetic waves by means of differential measurement. [Solution] This electromagnetic wave measurement probe includes a first measuring portion having a probe configuration comprising an electro-optic crystal exhibiting an electro-optic effect, an optical fiber which is provided on a base side of the electro-optic crystal and which transmits optical signals, and a reflecting portion which is provided on a distal end side of the electro-optic crystal and which reflects the optical signals, and a second measuring portion having a probe configuration, wherein, in first and second directions perpendicular to the axial direction of the optical fiber, the size of the electro-optic crystal is set to be at most equal to half the wavelength of the electromagnetic wave being measured, thereby enabling the electromagnetic wave to be measured with high precision.
A motor according to the present invention is provided with: a stator; a rotor; a cylindrical housing; and a neutralizer array that has a prescribed specific vibration frequency. The neutralizer array has at least one neutralizer group that includes a plurality of neutralizers arranged in the rotational axis direction. The motor generates vibration of a prescribed frequency in response to rotation of the rotor. A system from the vibration source of the motor to a connection part between the motor and a device has a transmission function which has properties of suppressing vibration of the connection part at the prescribed specific vibration frequency.
H02K 5/24 - EnveloppesEnceintesSupports spécialement adaptés pour la réduction ou à la suppression des bruits ou vibrations
B62D 5/04 - Direction assistée ou à relais de puissance électrique, p. ex. au moyen d'un servomoteur relié au boîtier de direction ou faisant partie de celui-ci
F16F 15/02 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif
9.
VOLUME MEASURING DEVICE AND VOLUME MEASURING METHOD
TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY (Japon)
ONO PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Mizutani Kosuke
Kato Taku
Nakane Keita
Horie Kengo
Ito Masafumi
Fujita Yasunori
Kawakami Kyojiro
Abrégé
The purpose of the present invention is to utilize blood PD-1 concentration as a biomarker for predicting a therapeutic effect of an immune checkpoint inhibitor on cancer, for evaluating cancer progression, or for predicting cancer recurrence. The present invention pertains to an agent for arresting cancer progression, for suppressing cancer recurrence, and/or for cancer treatment, the agent being characterized by containing an immune checkpoint inhibitor as an active ingredient and by being administered to cancer patients having a blood PD-1 concentration level less than a predetermined cutoff value.
The motor according to the present disclosure is provided with a stator, a rotor, a cylindrical housing, and a neutralizer having a predetermined natural frequency. The neutralizer has: an outer cover directly or indirectly fixed to the housing; an inner mass housed in a space formed by the outer cover and the outside surface of the housing; and one elastic member extending from the outer cover toward the space and supporting the inner mass so that the inner mass can vibrate in a plane including the circumferential direction and radial direction of the housing. Vibration having a predetermined frequency occurs in the motor in accordance with the rotation of the rotor, and a system from a vibration source of the motor to a connection portion between the motor and a device has a transfer function having a characteristic for suppressing the vibration of the connection portion at a predetermined natural frequency.
H02K 5/24 - EnveloppesEnceintesSupports spécialement adaptés pour la réduction ou à la suppression des bruits ou vibrations
F16F 15/02 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif
12.
HYDROGEN RECYCLE SYSTEM AND HYDROGEN RECYCLE METHOD
Provided are a hydrogen recycle system and a hydrogen recycle method, whereby hydrogen can be purified to high purity at high yield from a gas, said gas being exhausted from a nitride compound production device, and recycled. The hydrogen recycle system 1 comprises an exhaust gas supply path 11 supplying a gas exhausted from a nitride compound production device 2, a hydrogen recycle means 10 and a hydrogen supply path 12. The hydrogen recycle means 10 of the hydrogen recycle system 1 is characterized by comprising: a plasma reaction vessel 31 that defines at least a part of a discharge space 32; a hydrogen separation membrane 34 that divides the discharge space 32 from a hydrogen flow path 33 communicated with the hydrogen supply path 12, defines at least a part of the discharge space 32 by one surface thereof and also defines at least a part of the hydrogen flow path 33 by the other surface thereof; an electrode 35 that is disposed outside the discharge space 32; and an adsorbent 36 that is filled in the discharge space 32 and adsorbs the supplied exhaust gas.
C01B 3/56 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés
B01D 53/04 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
C01B 3/00 - HydrogèneMélanges gazeux contenant de l'hydrogèneSéparation de l'hydrogène à partir de mélanges en contenantPurification de l'hydrogène
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
C23C 16/44 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement
H01M 8/06 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus
13.
VIBRATION REDUCTION METHOD, MOTOR, NEUTRALIZER, AND ELECTRIC POWER STEERING DEVICE
A method for reducing vibrations in an electric power steering device to which a typical motor is attached includes: a step for determining the frequency of vibrations to be reduced in the electric power steering device, which is the frequency of the vibrations produced by the motor; and a step for setting the properties of a neutralizer provided on the housing of the motor in a manner such that the transfer function of the system from the source of vibrations in the motor to the coupling part between the motor and the electric power steering device is provided with properties which suppress the vibrations in the coupling part at the determined vibration frequency.
H02K 5/24 - EnveloppesEnceintesSupports spécialement adaptés pour la réduction ou à la suppression des bruits ou vibrations
B62D 5/04 - Direction assistée ou à relais de puissance électrique, p. ex. au moyen d'un servomoteur relié au boîtier de direction ou faisant partie de celui-ci
F16F 15/02 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif
14.
VIBRATION REDUCTION METHOD, MOTOR, NEUTRALIZER, AND ELECTRIC POWER STEERING DEVICE
This motor to be attached to a typical electric power steering device is equipped with a stator, a rotor capable of rotating relative to the stator, a housing which houses the stator and rotor therein and has a cylindrical shape which extends in the direction of the rotational axis of the rotor, and a neutralizer which is provided on the housing and extends in the radial direction of the housing from the lateral surface of the housing. Therein, vibrations of a prescribed frequency are produced in the motor according to the rotation of the rotor, the neutralizer has a prescribed unique vibration frequency, and the system from the source of vibrations in the motor to the coupling part between the motor and the electric power steering device has a transfer function provided with properties which suppress the vibrations in the coupling part at the prescribed unique vibration frequency.
H02K 5/24 - EnveloppesEnceintesSupports spécialement adaptés pour la réduction ou à la suppression des bruits ou vibrations
B62D 5/04 - Direction assistée ou à relais de puissance électrique, p. ex. au moyen d'un servomoteur relié au boîtier de direction ou faisant partie de celui-ci
F16F 15/02 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif
Provided is a hydrogen generating apparatus adaptable to fluctuating hydrogen demand, particularly by enabling large-scale hydrogen production, generating pure hydrogen at a high yield. The hydrogen generating apparatus 1 generates hydrogen gas from a source gas by decomposing the source gas through catalysis and transforming it into plasma through electric discharge. The hydrogen generating apparatus 1 includes a dielectric body 2 defining a source gas flow channel 13, a catalyst 10 that decomposes at least part of the source gas in the source gas flow channel 13 to generate hydrogen gas, an electrode 3 contacting the dielectric body 2, a hydrogen separation membrane 5 facing the electrode 3 across the dielectric body 2, a hydrogen flow channel 18 guiding hydrogen separated by the hydrogen separation membrane 5, and a high-voltage power supply 6 supplying power to cause electric discharge between the hydrogen separation membrane 5 and the electrode 3.
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
C01B 3/58 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés comportant une réaction catalytique
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
H01M 8/0656 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux par des moyens électrochimiques
16.
HYDROGEN PURIFICATION DEVICE AND HYDROGEN PURIFICATION METHOD
Provided are a hydrogen purification device and a hydrogen purification method whereby hydrogen having a high purity can be purified at a high yield from a starting gas. The hydrogen purification device 1 comprises: a starting gas source 9 that supplies a starting gas, said starting gas containing hydrogen molecules and/or a hydride, to a discharge space 3; a plasma reactor 2 that defines at least a part of the discharge space 3; a hydrogen flow channel 5 that is connected to the discharge space 3 and leads out purified hydrogen from the starting gas source 9; a hydrogen separation membrane 4 that partitions the discharge space 3 from the hydrogen flow channel 5, defines at least a part of the discharge space 3 by one surface thereof and defines at least a part of the hydrogen flow channel 5 by the other surface thereof; an electrode 7 that is positioned outside the discharge space 3; and an adsorbent 6 that is filled in the discharge space 3 and adsorbs the starting gas. In the hydrogen purification method according to the present invention, the starting gas is adsorbed by the adsorbent 6 in the discharge space 3. Hydrogen molecules, which have been desorbed from the adsorbent 6 by discharge, are allowed to penetrate through the hydrogen separation membrane 4 and led out into the hydrogen flow channel 5.
C01B 3/56 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés
B01D 53/04 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
17.
DEVICE PROVIDED WITH COMPOSITE IMMOBILIZED ON SUPPORT, AND BIOSENSOR
Provided is a device such as a biosensor wherein a biomolecule and/or an organic compound is simply immobilized on a support so as to enable the occurrence of at least one phenomenon selected from among reaction, flow-out, flow-in and retention of the biomolecule and/or the organic compound. The device according to one embodiment comprises a porous support and a composite immobilized on the support, wherein: the composite comprises a microfibrous cellulose, said microfibrous cellulose having a number-average fiber diameter of 2-150 nm, having a cellulose I type crystalline structure and being anion-modified, and a biomolecule and/or an organic compound; one or more independent areas having the composite immobilized thereon are formed within the support; and, when water penetrates into the areas, at least one phenomenon selected from among reaction, flow-out, flow-in and retention of the biomolecule and/or the organic compound occurs.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
C12Q 1/46 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase une estérase une cholinestérase
18.
Double-stranded nucleic acid molecule and use thereof
A double-stranded nucleic acid molecule includes a first polynucleotide chain including a base sequence represented by Chemical Formula (1) (SEQ ID NO:1) and a second polynucleotide chain including a base sequence complementary to the first polynucleotide chain. A method for preventing and/or treating a tumor includes a step in which the double-stranded nucleic acid molecule is administered to a test subject.
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
National University Corporation Nagoya University (Japon)
Gifu University (Japon)
Gifu Prefecture (Japon)
Inventeur(s)
Yamamoto, Tokunori
Suzuki, Satoshi
Funahashi, Yasuhito
Matsukawa, Yoshihisa
Gotoh, Momokazu
Kitayama, Tomohiro
Hoshino, Yoichiro
Murase, Tetsuma
Abrégé
It is an object to provide a technique useful for embryo transfer and development of reproductive medical care. Provided are a sperm activator containing a disrupted product of one or more cells selected from the group consisting of adipose tissue-derived stem cells, dental pulp-derived stem cells, bone marrow-derived stem cells, and umbilical cord blood-derived stem cells as an active ingredient, and an artificial insemination method utilizing the same.
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61K 35/52 - SpermeProstateLiquide séminalCellules de Leydig des testicules
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
Provided is a hydrogen generating apparatus adaptable to fluctuating hydrogen demand, particularly by enabling large-scale hydrogen production, generating pure hydrogen at a high yield. The hydrogen generating apparatus 1 includes a tabular dielectric body 2 having a first surface 11 with a source gas flow channel 13 formed as a recess and a second surface 12 approximately parallel to the first surface 11, a grounding electrode 3, a hydrogen flow channel plate 4 with a hydrogen flow channel 18 and a hydrogen outlet 19, being arranged on a first surface 11 side of dielectric body 2, a hydrogen separation membrane 5 between source gas flow channel 13 and hydrogen flow channel 18, and a high-voltage power supply 6 that causes electric discharge in source gas flow channel 13 between hydrogen separation membrane 5 and grounding electrode 3. Hydrogen separation membrane 5 transmits hydrogen generated by electric discharge in source gas flow channel 13 into hydrogen flow channel 18.
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
H01M 8/0606 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
C01B 3/56 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés
Provided are: a nucleoside that is more suitable for practical use such as an RNA medicine or the like; and the use of the nucleoside. For this purpose, provided is a nucleoside derivative represented by formula (1) or (2) or a salt thereof. [Chem. 16] (In formula (1), R1represents a hydrogen atom, a hydroxy group, a hydroxy group in which a hydrogen atom is substituted with an alkyl group or an alkenyl group, or a protected group, and in formula (2), X represents a halogen atom. In formula (1) and formula (2), R2and R3nnR5R6(n represents 0 or 1, R5and R6may be the same or different and each represent a hydrogen atom, a hydroxy group, a protected hydroxy group, a mercapto group, a protected mercapto group, a lower alkoxy group, a cyano lower alkoxy group, an amino group, or a substituted amino group. Note that when n is 1, R5and R6would not simultaneously be a hydrogen atom.), each R4represents NHR7having a linking group (R7 represents a hydrogen atom, an alkyl group, an alkenyl group, or a protecting group for amino group), an azide group, an amidino group, or a guanidino group, and B represents one of a purin-9-yl group, a 2-oxo-pyrimidin-1-yl group, a substituted purin-9-yl group, or a substituted 2-oxo-pyrimidin-1-yl group.)
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07H 19/10 - Radicaux pyrimidine avec le radical saccharide estérifié par des acides phosphoriques ou polyphosphoriques
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 23/00 - Composés contenant du bore, du silicium ou un métal, p. ex. chélates ou vitamine B12
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
Provided is an anomalous item determination method with which it is possible to determine an anomalous item accurately by performing machine learning using a large amount of normal data and a small quantity of anomalous data. Data relating to a plurality of items to be determined are input into an encoder-decoder structure network, features of the items to be determined are extracted, and a discriminator determines whether the distribution of the features of the items to be determined is in accordance with a normal distribution. Updating of the encoder-decoder structure network, updating of the discriminator, and updating of an encoder are each repeated to minimize a feature extraction error. The encoder, using a feature obtained by the updating, calculates an anomaly degree of the items to be determined, subjects the anomaly degree to threshold value processing, and determines whether the items to be determined are normal items or anomalous items. The step of determining whether the distribution of the features of the items to be determined is in accordance with a normal distribution comprises a step of inputting data in accordance with a normal distribution into the discriminator and calculating an error between the data and the features of the items to be determined extracted by the encoder-decoder structure network. Using the result of determination by the discriminator allows the features of the items to be determined that are used by the encoder for anomaly degree calculation to converge so as to be distributed in accordance with a normal distribution.
Provided are: a method for producing an α-aluminum oxide particle, whereby a particle having a smaller particle size and high dispersibility can be produced with high purity; and an α-aluminum oxide particle produced by the production method. An α-aluminum oxide particle having a Feret diameter of at least 2 nm and less than 20 nm and a circularity of 0.82-0.86 is produced by a production method in which amorphous aluminum hydroxide, water, and carboxylic acid are mixed and stirred to prepare a precursor sol of α-aluminum oxide, and the undried precursor sol or a dried matter of the precursor sol is rapidly heated for 0.1-60 seconds from room temperature to a temperature range of 1000-1200°C, and the rapidly heated matter is rapidly cooled for 1 second to 10 minutes from the temperature range of 1000-1200°C to a temperature range of room temperature to 100°C.
C01F 7/44 - Déshydratation de l’oxyde ou de l'hydroxyde d'aluminium, c.-à-d. toutes les conversions d'une forme en une autre impliquant une perte d’eau
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
24.
COMPOSITE COMPOSITION, METHOD FOR PRODUCING SAME AND BIOSENSOR
Provided is a composite composition which is capable of stabilizing biomolecules. A composite composition according to one embodiment of the present invention contains biomolecules and anion-modified cellulose nanofibers that have a cellulose I type crystal structure; and this composite composition has a moisture content of 20% by mass or less. This composite composition is able to be obtained by mixing biomolecules and an aqueous dispersion of anion-modified cellulose nanofibers that have a cellulose I type crystal structure and subsequently drying the mixture until the moisture content thereof comes to 20% by mass or less. This composite composition is able to be used, for example, for a biosensor.
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
B82Y 40/00 - Fabrication ou traitement des nanostructures
C08J 3/21 - Formation de mélanges de polymères avec des additifs, p. ex. coloration en présence d'une phase liquide le polymère étant prémélangé avec une phase liquide
C08L 89/00 - Compositions contenant des protéinesCompositions contenant leurs dérivés
Provided is a hydrogen generator which can flexibly respond to the change of supply quantity of hydrogen, and particularly, can easily respond to hydrogen mass production and can generate highly pure hydrogen in high yield. A hydrogen generator 1 generates hydrogen gas from raw material gas in high yield through decomposition by a catalyst and plasma gasification of the raw material gas by electric discharge. The hydrogen generator 1 comprises: a dielectric 2 that defines a raw material gas flow path 13; a catalyst 10 that generates hydrogen gas by decomposing at least part of raw material gas flowing through the raw material gas flow path 13; an electrode 3 that is disposed so as to be in contact with the dielectric 2; a hydrogen separation membrane 5 that faces the electrode 3 via the dielectric 2; a hydrogen flow path 18 through which hydrogen separated by the hydrogen separation membrane 5 is delivered; and a high voltage power source 6 that supplies electric power so as to generate electric discharge between the hydrogen separation membrane 5 and the electrode 3.
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
C01B 3/56 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés
H01M 8/0656 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux par des moyens électrochimiques
[Problem] To provide a hydrogen generator capable of easily controlling the amount of hydrogen generated, and capable of generating high-purity hydrogen with a high yield. [Solution] A hydrogen generator 1 comprises a dielectric 2, an electrode 3, a hydrogen separation membrane 5, and a high voltage power supply 6. The dielectric 2 is of a flat plate configuration that has a first surface 11 in which a raw material gas flow path 13 is formed as a continuous groove, and a second surface 12 that is substantially parallel to the first surface 11. The electrode 3 is disposed facing the second surface 12 of the dielectric 2, and the hydrogen separation membrane 5 is disposed on the first surface 11 side of the dielectric 2. The hydrogen separation membrane 5 covers the opening of the raw material gas flow path 13. The high voltage power supply 6 supplies power to the electrode 3 or the hydrogen separation membrane 5 and generates electric discharge. The electrode 3 and the hydrogen separation membrane 5 are disposed in asymmetric positions relative to the dielectric 2.
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
C01B 3/56 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés
H01M 8/0656 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux par des moyens électrochimiques
Provided is an apparatus for measuring the thickness, roughness, and morphology index of the mandibular cortical bone using a dental panorama image to assist in the diagnosis of osteoporosis, wherein the thickness, roughness, and morphological index of the cortical bone is measured more accurately and the diagnosis of osteoporosis can be supported more accurately. An osteoporosis diagnostic support apparatus, wherein the apparatus has a contour extraction unit adapted to extract a mandibular contour from an image of a mandibular cortical bone photographed by a photographic apparatus adapted to photograph the mandibular cortical bone and surroundings thereof, a line segment extraction unit adapted to extract line segments from the image of the mandibular cortical bone photographed by the photographic apparatus; and a cortical bone thickness calculation unit adapted to calculate a thickness of the cortical bone based on the extracted mandibular contour and line segments.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
[Problem] To provide a strain not pathogenic to plants which exhibits a stable bacterial plant disease control effect at real crop production sites and which can be safely used as a biological pesticide, and to provide a bacterial plant disease control agent using said strain. [Solution] By using, as an active component, live bacteria, or a culture containing said live bacteria, of a bacterial strain of the genus Mitsuaria, which is not conventionally know to have a bacterial plant disease control effect, it is possible to provide a bacterial plant disease control agent such as a vegetable wilt disease control agent or a surface rot control agent.
A01C 1/00 - Appareils ou modes d'emploi des appareils pour éprouver ou traiter les graines, les racines ou analogues avant l'ensemencement ou la plantation
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
[Problem] To provide a new strain not pathogenic to plants which exhibits a stable bacterial plant disease control effect at real crop production sites and which can be safely used as a biological pesticide, and to provide a bacterial plant disease control agent using said strain. [Solution] By using, as an active component, live bacteria, or a culture containing said live bacteria, of the Ralstonia pickettii TCR 112 strain (NITE BP-02446), it is possible to provide a bacterial plant disease control agent such as a vegetable wilt disease control agent or a surface rot control agent.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
A01N 63/02 - Substances produites par, ou obtenues à partir de micro-organismes ou d'animaux
[Problem] To provide a bacterial plant disease control agent which has a stable plant disease control effect at real crop production sites and which can be safely used as a biological pesticide. [Solution] By using in combination, as active components, live bacteria, or a culture containing said live bacteria, of a strain belonging to the genus Mitsuaria having a bacterial plant disease control effect and a strain belonging to the genus Ralstonia not pathogenic to plants and having a bacterial plant disease control effect, it is possible to provide a bacterial plant disease control agent such as a vegetable wilt disease control agent or a surface rot control agent.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
Provided are an outer cylinder for a hydraulic shock absorber having excellent productivity, and a method for molding the outer cylinder for a hydraulic shock absorber. The outer cylinder for a hydraulic shock absorber is provided with an intermediate body (20) and an outer case main body (10A). The intermediate body (20) has continuous reinforcing fibers knitted (textile-processed) in a tubular form. The outer case main body (10A) is molded from a polyamide resin that is a thermoplastic resin that forms irregularities on the outside of the intermediate body (20) while impregnating the intermediate body (20). Textile processing is a process for assembling, weaving, or knitting fibers to produce a flat or tubular fabric, cord, etc.
B29C 45/14 - Moulage par injection, c.-à-d. en forçant un volume déterminé de matière à mouler par une buse d'injection dans un moule ferméAppareils à cet effet en incorporant des parties ou des couches préformées, p. ex. moulage par injection autour d'inserts ou sur des objets à recouvrir
B29C 70/24 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant uniquement des renforcements, p. ex. matières plastiques auto-renforçantes des renforcements fibreux uniquement caractérisées par la structure des renforcements fibreux utilisant des fibres de grande longueur, ou des fibres continues orientées dans au moins trois directions formant une structure tridimensionnelle
F16F 9/32 - Ressorts, amortisseurs de vibrations, amortisseurs de chocs ou amortisseurs de mouvement de structure similaire, utilisant un fluide ou moyen équivalent comme agent d'amortissement Parties constitutives
A hydrogen generator is provided which can flexibly respond to changes in the amount of hydrogen supplied, and which in particular can easily handle mass production of hydrogen and can moreover generate high purity hydrogen with a high yield. This hydrogen generator 1 is provided with: a plate-shape dielectric 2 having a first surface 11 comprising a raw material gas flow path 13 formed as a recess and a second surface 12 approximately parallel to the first surface 11; a ground electrode 3; a hydrogen flow path plate 4 having a hydrogen flow path 18 and a hydrogen outlet 19 and arranged on the first surface 11 side of the dielectric 2; a hydrogen separation membrane 5 which is arranged between the raw material gas flow path 13 of the dielectric 2 and the hydrogen flow path 18 of the hydrogen flow path plate 4 and which partitions the raw material gas flow path 13 and the hydrogen flow path 18; and a high voltage power supply 6 which generates electric discharge inside of the raw material gas flow path 13 between the hydrogen separation membrane 5 and the ground electrode 3. Hydrogen generated from the raw material gas by electric discharge in the raw material gas flow path 13 is passed by the hydrogen separation membrane 5 into the hydrogen flow path 18 of the hydrogen flow path plate 4.
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
C01B 3/56 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés
H01M 8/06 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus
H01M 8/0606 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux
33.
FUEL BATTERY SYSTEM PROVIDED WITH HYDROGEN GENERATOR
A compact fuel battery system is provided that has an integrated hydrogen generator. This fuel battery system 1 is provided with a hydrogen generator 10 and a fuel battery cell 20. The hydrogen generator 10 is provided with a plate-shape dielectric 2 having a raw material gas flow path surface 11 in which a raw material gas flow path 13 is formed. An electrode 3 faces the back surface 12 of the dielectric 2. A hydrogen separation membrane 5, which has a first surface 18 and the second surface 19, closes an opening of the raw material gas flow path 13. Furthermore, the hydrogen generator 10 is provided with a high-voltage power supply 6 which generates electric discharge between the hydrogen separation membrane 5 and the electrode 3. The fuel battery system is characterized in that the second surface 19 of the hydrogen separation membrane 5 of the hydrogen generator is arranged facing the fuel electrode 21 of the fuel battery cell 20.
H01M 8/0606 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
C01B 3/56 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés
H01M 8/10 - Éléments à combustible avec électrolytes solides
An MFI type zeolite membrane to be formed on a porous inorganic oxide substrate, wherein, in an X-ray diffraction pattern obtained by X-ray diffractometry measurement using CuKα ray as an X-ray source, the intensity of a diffraction peak assignable to crystal lattice plane of the 200 and/or 020 planes, said peak appearing at a diffraction angle of 8.4-9.0°, is 0.3 or greater, using the intensity of a diffraction peak assignable to crystal lattice plane of the 011 and/or 101 planes, said peak appearing at a diffraction angle of 7.3-8.4°, as a reference.
A method for producing a separation membrane in which: a zeolite film is formed on an inorganic oxide porous substrate; and the main component of a zeolite formation part of the substrate is amorphous SiO2. This method for producing a separation membrane comprises: a first step wherein a seed crystal of zeolite and an alkali component containing a structure-directing agent are formed on the surface of the substrate; and a second step wherein a formed body obtained in the first step is processed in a heated water vapor atmosphere. Consequently, a zeolite film is formed on the substrate surface in this method for producing a separation membrane.
[Problem] To provide a nucleoside that is more practical for RNA pharmaceuticals and other applications and a use therefor. [Solution] A nucleoside derivative indicated by formula (1) or (2) or a salt thereof. (In formula (1), R1 indicates a hydrogen atom, a hydroxyl group, a hydroxyl group having a hydrogen atom substituted by an alkyl group or an alkenyl group, or a protected group. In formula (2), X indicates a halogen atom. In formulas (1) and (2), R2 and R4 can be the same or different and indicate a hydrogen atom, a protecting group for a hydroxyl group, a phosphate group, a protected phosphate group, or –P(=0)nR5R6 (n indicates 0 or 1 and R5 and R6 can be the same or different and indicate either a hydrogen atom, a hydroxyl group, a protected hydroxyl group, a thiol group, a protected thiol group, a lower alkoxy group, a cyano lower alkoxy group, an amino group, or a substituted amino group. When n is 1, however, R5 and R6 are never both hydrogen atoms.) R3 indicates NHR7 having a linking group for each (R7 indicating a hydrogen atom, an alkyl group, an alkenyl group, or a protecting group for an amino group), an azide group, an amidino group, or a guanidino group. B indicates a purine-9-yl group, a 2-oxo-pyrimidin-1-yl group, a substituted purine-9-il group, or a substituted 2-oxo-pyrimidin-1-yl group.)
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07H 19/067 - Radicaux pyrimidine avec un ribosyle comme radical saccharide
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (Japon)
GIFU UNIVERSITY (Japon)
SOWAKAI MEDICAL FOUNDATION (Japon)
Inventeur(s)
Nishiyama Akira
Matsuyama Makoto
Ebihara Akio
Abrégé
Provided is a novel antibody against a prorenin receptor or an antigen-binding fragment of the antibody, which can detect a prorenin receptor. The antibody against a prorenin receptor or an antigen-binding fragment of the antibody according to the present invention is characterized by being capable of binding to a prorenin receptor, and is also characterized by comprising a heavy-chain variable region and a light-chain variable region, wherein the combination of the heavy-chain variable region and the light-chain variable region is as follows: the heavy-chain variable region contains the amino acid sequences (H1-a1), (H2-a1) and (H3-a1) and the light-chain variable region contains the amino acid sequences (L1-a1), (L2-a1) and (L3-a1).
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
[Problem] To provide a double-stranded nucleic acid molecule exhibiting excellent antitumor activity. [Solution] A double-stranded nucleic acid molecule containing a first polynucleotide chain which includes a base sequence represented by chemical formula (1) (SEQ ID NO: 1), and a second polynucleotide chain which includes a complementary base sequence to the first polynucleotide chain.
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (Japon)
GIFU UNIVERSITY (Japon)
GIFU PREFECTURE (Japon)
Inventeur(s)
Yamamoto Tokunori
Suzuki Tetsu
Funahashi Yasuhito
Matsukawa Yoshihisa
Gotoh Momokazu
Kitayama Tomohiro
Hoshino Yoichiro
Murase Tetsuma
Abrégé
The present invention addresses the problem of providing a technology that is useful for the progress in reproductive medicine and fertilized egg transplantation. Provided are: a sperm activator that contains, as an active ingredient, a material obtained by crushing at least one type of cells selected from the group consisting of fat tissue-derived stem cells, dental pulp-derived stem cells, bone marrow-derived stem cells, and umbilical cord-derived stem cells; and an artificial insemination method using the sperm activator.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
40.
GRAFT MATERIAL FOR TREATING NERVE DAMAGE INCLUDING DENTAL PULP CELLS
ADVANCED CELL TECHNOLOGY AND ENGINEERING LTD. (Japon)
Inventeur(s)
Tezuka Kenichi
Sugiyama Ken
Abrégé
Provided is a graft material for treating nerve damage, the graft material including dental pulp cells, wherein properties required of dental pulp cells provided as a graft material for treating nerve damage are identified. The present invention pertains to a graft material for treating nerve damage, the graft material including dental pulp cells in which GABRB1 genes are expressed and which are resistant to active oxygen.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
41.
Energy storage transportation method and energy carrier system
An energy carrier system is provided that produces ammonia with high efficiency and that further produces hydrogen as final product and uses the hydrogen as energy. An energy storage transportation method is further provided that is carried out by using energy carrier system. The energy carrier system includes nitric acid production device, an ammonia production device, and hydrogen production device. The nitric acid production device includes a photo-reactor, a gas supply unit that supplies photo-reactor with gas to be treated containing a nitrogen oxide, water, and oxygen, and light source disposed in the photo-reactor. The light source radiates light including ultraviolet of a wavelength shorter than 175 nm. The energy storage transportation method includes nitric acid production step of producing nitric acid from a nitrogen oxide, ammonia production step of producing ammonia through reduction of nitric acid, and hydrogen production step of producing hydrogen through decomposition of the ammonia.
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (Japon)
GIFU UNIVERSITY (Japon)
Inventeur(s)
Suzuki Masaaki
Ito Kengo
Natsume Atsushi
Ikenuma Hiroshi
Koyama Hiroko
Abrégé
[Problem] To provide 11C-labelled O6-benzylguanine with which PET images can be obtained, and a production method therefor. [Solution] This 11C-labelled O6-benzylguanine is characterized by being represented by chemical formula (a). The compound is obtained by performing: a coupling step in which 11C-labelled methyl iodide and an organic tin compound (b) (with the caveat that, in chemical formula (b), R1 represents an alkyl group, and R2 and R3 represent elimination groups which are capable of being eliminated by bases) in an aprotic lactam are cross-coupled in the presence of a palladium complex and a phosphine ligand; and an elimination step in which elimination groups R2 and R3 of the cross-coupling product obtained as a result of the coupling step are eliminated by bases.
C07D 473/18 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 un atome d'oxygène et un atome d'azote, p. ex. guanine
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
The present invention makes it possible to provide good grasping performance with low energy consumption. A hand robot control method comprises: a first step of causing, by energizing a plurality of motors for the fingers in a prescribed order, each joint corresponding to a motor to bend; a second step of placing a joint into a locked state with a one-way power transmission mechanism each time a detection is made by a tactile sensor means by de-energizing the motor of the joint corresponding to that tactile sensor means that has made the detection; a third step of causing the joint corresponding to the motor to bend by energizing the prescribed motor under the condition that all motors are de-energized; and a fourth step of placing all joints in a locked state by de-energizing all motors including the prescribed motor under the condition that the grasping force based on a detected value of the tactile sensor means is a target grasping force.
Provided is a novel prophylactic or therapeutic agent for various diseases caused by IL-18 activity, more specifically, a medicine that comprises a peptide selected from the group consisting of (a) to (c) or a salt thereof: (a) a peptide containing an amino acid sequence represented by SEQ ID NO:1; (b) a peptide containing an amino acid sequence having at least 60% identity to the amino acid sequence represented by SEQ ID NO:1 and having an effect of inhibiting IL-18 activity; and (c) a peptide having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 by deletion, substitution, insertion and/or addition of one or more amino acid residues and having an effect of inhibiting IL-18 activity.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is a nucleoside derivative represented by formula (1). (In formula (1), Y represents an unfused aromatic or heterocyclic hydrocarbon group or a fused polycyclic based hydrocarbon group, W1 represents a hydrogen atom, a hydroxyl group-protecting group, or a phosphate ester group, W2 represents a hydrogen atom, a hydroxyl group-protecting group, or a phosphate ester group, and R1, R2, and R3 each independently represent a hydrogen atom or a linear saturated hydrocarbon group having 1-4 carbon atoms.)
C07D 239/47 - Un atome d'azote et un atome d'oxygène ou de soufre, p. ex. cytosine
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 239/54 - Deux atomes d'oxygène liés par une liaison double ou sous forme de radicaux hydroxyle non substitués
C07D 473/18 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 un atome d'oxygène et un atome d'azote, p. ex. guanine
C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
[Problem] To provide a shaft that is lightweight and has excellent strength. [Solution] A shaft 6 has one or a plurality of fiber-reinforced resin layers. At least one of the fiber-reinforced resin layers is manufactured by the filament winding method in which one or a plurality of fiber bundles are wound while applying tension. Each fiber bundle includes a plurality of filaments. The tension applied to the fiber bundle is at least 0.04 gf per filament. This tension is high. Preferably, at least one of the fiber-reinforced resin layers is manufactured by the multi-filament winding method, in which a plurality of the fiber bundles are simultaneously wound while being disposed in parallel. Preferably, the fiber constituting the filament is carbon fiber. Preferably, the resin composition included in the fiber-reinforced resin layer is an epoxy resin composition.
A denitration device and a denitration method in which denitration is performed efficiently and in a stable manner in a lower-reaction-temperature region without using a catalyst. The denitration device is provided with a combustion chamber, a denitration agent feed means for feeding a denitration agent into the combustion chamber, an exhaust pipe, and an OH-radical-generating substance feed means for feeding an OH radical-generating substance into the exhaust pipe. The denitration agent feed means feeds a denitration agent into the exhaust gas of the combustion chamber to perform a first denitration reaction step, and the OH-radical-generating substance feed means feeds the OH-radical-generating substance into the exhaust gas in the exhaust pipe to perform a second denitration reaction step.
F23J 7/00 - Aménagement des dispositifs d'introduction de produits chimiques dans le foyer
F23G 7/06 - Procédés ou appareils, p. ex. incinérateurs, spécialement adaptés à la combustion de déchets particuliers ou de combustibles pauvres, p. ex. des produits chimiques de gaz d'évacuation ou de gaz nocifs, p. ex. de gaz d'échappement
F23J 15/00 - Aménagement des dispositifs de traitement de fumées ou de vapeurs
48.
OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING SAME, AND METHODS FOR PRODUCING THESE
[Problem] To provide a novel oligonucleotide derivative that is easy to synthesize and can be introduced into cells without using a lipofection reagent. [Solution] The oligonucleotide derivative of the present invention is shown by, e.g., (1). This derivative is considered to bind an aminoglycan moiety to a ligand on the surface of a cell and be introduced into the cell, and can be expected to have selective drug delivery functions. In the formula, R1 and R2 each independently represent a hydrogen or phosphate group; a, b, and c independently represent integers of 0 or higher, at least one of a, b, and c being 1 or higher; A and B independently represent optionally modified oligonucleotides having a combined chain length of A and B of 3 or higher. However, A and B do not include hydroxyl groups at the 3' end and 5' end of the oligonucleotide. Furthermore, S in the formula indicates a sugar substituent, a peptide chain, or a tocopherol binding group. Additionally, an alkyl group may be bonded, in lieu of hydrogen, to the benzene ring in the formula.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
49.
ENERGY STORAGE TRANSPORTATION METHOD AND ENERGY CARRIER SYSTEM
Provided are: an energy carrier system which produces ammonia with high efficiency, and eventually produces hydrogen from the ammonia and uses the same as energy; and an energy storage transportation method using the system. This energy carrier system comprises nitric acid production means, ammonia production means, and hydrogen production means. The nitric acid production means includes: a photoreactor; a processed gas supplying means which supplies a processed gas containing nitrogen oxide, water, and oxygen to the photoreactor; and a light source which is disposed inside the photoreactor and generates light that includes ultraviolet rays with a wavelength of less than 175 nm. This energy storage transportation method comprises: a nitric acid production step of producing nitric acid from nitrogen oxide; an ammonia production step of producing ammonia by reducing the nitric acid; and a hydrogen production step of producing hydrogen by decomposing the ammonia.
[Problem] To provide a new tetrazole derivative and antiviral agent targeting the RNA polymerase of a virus. [Solution] An antiviral agent according to the present invention is characterized by comprising, as an active ingredient, a tetrazole derivative represented by chemical formula (1), or a pharmaceutically acceptable salt, hydrate or solvate thereof. In formula (1), R1 represents an alkylbenzene substituent group, a halogenated benzene substituent group or (1-a), and X represents O-R2 or (1-b) (therein, R2 represents an alkenyl group or an alkyl group having four or less carbon atoms, and R3 an R4 each independently represent a hydrogen atom, an alkyl group, an alkenyl group, an aromatic substituent group or a heteroaromatic substituent group).
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Tezuka, Kenichi
Tamaoki, Naritaka
Iida, Kazuki
Kawaguchi, Tomoko
Aoki, Hitomi
Kunisada, Takahiro
Shibata, Toshiyuki
Goshima, Naoki
Abrégé
A method that includes bringing a nuclear reprogramming substance (DLX4 gene, OCT3/4 gene, and SOX2 gene) into contact with a cell and thereby producing iPS cells.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
The present invention provides a highly safe composition for suppressing cancer cell proliferation (composition for preventing/treating cancer). This composition for suppressing cancer cell proliferation includes a green tea extract and a rosemary extract at a weight ratio (mixture weight ratio of green tea extract : rosemary extract) of 10:1 to 1:10.
A braider and a tube body in which braids are arranged on an outer peripheral surface of a mandrel uniformly even if the diameter of the mandrel is uneven. A braider 1 has bobbin carrier conveyance mechanisms 50A and 50B in which bobbin carriers 40A and 40B are conveyed from traveling tracks W1 and W2 to an outside of the traveling tracks W1 and W2 so as to stop winding of braids Y1 and Y2 onto a mandrel 2 and the bobbin carriers 40A and 40B are conveyed from the outside of the traveling tracks W1 and W2 to the traveling tracks W1 and W2 so as to start the winding of the braids Y1 and Y2 onto the mandrel 2.
D04C 3/28 - Dispositifs pour commander les porte-bobines afin d'obtenir des dessins, p. ex. dispositifs sur guides ou platines en arrêtant uniquement les porte-bobines
54.
Hydrogen generating apparatus and fuel cell system provided with hydrogen generating apparatus
To provide a hydrogen generating apparatus that efficiently generates hydrogen from ammonia, and a fuel cell system that generates power using the efficiently generated hydrogen. [Solution] A hydrogen generating apparatus (1) is provided with a plasma reactor (3), a high-voltage electrode (5), a grounding electrode (7), and a gas supply means (15) that supplies a gas containing ammonia to the plasma reactor. The high-voltage electrode (5) is configured with a hydrogen separation membrane (12) included therein. Under the conditions of room temperature and atmospheric pressure, the hydrogen separation membrane (12) of the high-voltage electrode (5) discharges electricity between the grounding electrode (7) and the hydrogen separation membrane with power supplied from a high-voltage pulse power supply (2), and hydrogen is generated by bringing into the plasma state the ammonia contained in the gas thus supplied.
B01J 19/18 - Réacteurs fixes avec éléments internes mobiles
H01M 8/06 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus
B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
C01B 3/50 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification
H01M 8/0606 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux
H01M 8/0662 - Traitement des réactifs gazeux ou des résidus gazeux, p. ex. nettoyage
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
55.
MALEATE OF ANTI-PRION COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION THEREOF
The problem addressed by the present invention is to provide an anti-prion compound having high crystallinity and high crystal stability, and to provide an agent for the prevention, amelioration, and treatment of prion disease. The present invention is a maleate of the compound represented in formula (1).
C07D 295/14 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Provided is a device for measuring the thickness, roughness, and morphology index of the mandibular cortical bone using a dental panorama image to assist in the diagnosis of osteoporosis, wherein the thickness, roughness, and morphology index of the cortical bone is measured more accurately and the diagnosis of osteoporosis can be supported more accurately. A device for assisting in the diagnosis of osteoporosis, wherein the device has an outline extraction unit for extracting a mandibular bone outline from an image of a mandibular cortical bone captured by an imaging device for capturing an image of the mandibular cortical bone and the surroundings thereof, a line segment extraction unit for extracting a line segment from the image of the mandibular cortical bone captured by the imaging device, and a cortical bone state calculator or a cortical bone morphology indicator identification unit for calculating the state of the cortical bone on the basis of the extracted mandibular bone outline and line segment.
A61B 6/14 - Applications ou adaptations à l'art dentaire
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
57.
NON-CATALYTIC DENITRATION DEVICE AND NON-CATALYTIC DENITRATION METHOD
To apply a denitration device and a denitration method in which denitration is performed efficiently and in a stable manner in a lower-reaction-temperature region without using a catalyst. The denitration device (100) is provided with a combustion chamber (1), a denitration agent feed means (11) for feeding a denitration agent into the combustion chamber (1), an exhaust pipe (2), and an OH-radical-generating substance feed means (21) for feeding an OH-radical-generating substance into the exhaust pipe (2). The denitration agent feed means (11) feeds a denitration agent into the exhaust gas of the combustion chamber to perform a first denitration reaction step, and the OH-radical-generating substance feed means (21) feeds the OH-radical-generating substance into the exhaust gas in the exhaust pipe (2) to perform a second denitration reaction step.
F23G 7/06 - Procédés ou appareils, p. ex. incinérateurs, spécialement adaptés à la combustion de déchets particuliers ou de combustibles pauvres, p. ex. des produits chimiques de gaz d'évacuation ou de gaz nocifs, p. ex. de gaz d'échappement
F23J 7/00 - Aménagement des dispositifs d'introduction de produits chimiques dans le foyer
F23J 15/00 - Aménagement des dispositifs de traitement de fumées ou de vapeurs
The purpose of the present invention is to provide: a formate dehydrogenase having a high specific activity; and a method for producing a formate dehydrogenase with high efficiency without using methanol. The present invention relates to: a novel formate dehydrogenase; a gene encoding the formate dehydrogenase; a method for producing the formate dehydrogenase; and a method for regenerating a coenzyme using the formate dehydrogenase.
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
This molding jig manufacturing method (1) is provided with: a molten film forming step (S1) for forming a mold release film (3) on a substrate surface (6a) of a substrate (6) by applying a powdery PTFE resin (7) to the substrate surface (6a) and heating the resin, said substrate being a substrate on which a film is to be formed; a plasma modifying step (S2) as a surface modifying step for irradiating a film surface (3a) of the mold release film (3) with plasma; a prepreg laminating step (S3) for laminating, on a modified film surface (3b) of the mold release film (3), a sheet-like prepreg (4) configured from a carbon fiber; and a firing step (S4) for performing firing in a state wherein the mold release film (3) and the prepreg (4) are laminated.
B29C 70/06 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant uniquement des renforcements, p. ex. matières plastiques auto-renforçantes des renforcements fibreux uniquement
61.
RNA INTERFERENCE AGENT, METHOD FOR PRODUCING SAME, AND USE THEREOF
Provided is an RNA interference agent having a simple structure, and with which it possible to obtain an effect of suppressing an off-target effect. In order to achieve this aim, the present invention is an RNA interference agent, comprising one or more PAZ domain low-affinity units on the 3' terminal, and provided with a single-strand oligonucleotide as a passenger strand.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
62.
REDOX PAIR, AND PHOTOELECTRIC CONVERSION ELEMENT PRODUCED USING SAME
Provided are: a redox pair which does not have strong absorption in a visible region unlike a iodine redox pair, can be sealed readily, and has high performance; and a photoelectric conversion element which is produced using the redox pair and has high practical availability. A redox pair composed of a compound represented by general formula (1) and a compound represented by general formula (2) is used. In general formula (1), A represents Li, K, Na, an ammonium compound, an imidazolium compound or a pyrrolidinium compound. In general formulae (1) and (2), R1 represents a linear alkyl group having 4 to 8 carbon atoms, wherein multiple R1's are the same as or different from each other or some or all of the multiple R1's are different from each other. AA General formula
H01M 14/00 - Générateurs électrochimiques de courant ou de tension non prévus dans les groupes Leur fabrication
C07D 207/06 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux contenant uniquement des atomes d'hydrogène et de carbone, liés aux atomes de carbone du cycle
C07D 233/58 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés aux atomes de carbone du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés aux atomes d'azote du cycle
H01L 31/04 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails adaptés comme dispositifs de conversion photovoltaïque [PV]
63.
REINFORCING FIBER/RESIN FIBER COMPOSITE FOR PRODUCTION OF CONTINUOUS-FIBER-REINFORCED THERMOPLASTIC RESIN COMPOSITE MATERIAL AND PROCESS FOR MANUFACTURING SAME
The present invention provides a technique for impregnating a continuous fiber with a thermoplastic resin having a high melt viscosity in a short time, and thereby enables short-cycle molding of a continuous-fiber-reinforced thermoplastic resin composite material. The present invention pertains to a reinforcing fiber/resin fiber composite (10) which is to be used for the production of a continuous-fiber-reinforced thermoplastic resin composite material and which is characterized in that: the composite (10) comprises a continuous fiber bundle (1) and a thermoplastic resin fiber (cover (2)) which covers the periphery of the continuous fiber bundle (1) in such a state that the continuous fiber bundle (1) is not constricted; and the continuous fiber bundle (1) can be flattened. The present invention also pertains to a process for manufacturing the same.
C08J 5/04 - Renforcement des composés macromoléculaires avec des matériaux fibreux en vrac ou en nappes
B29B 11/16 - Fabrication de préformes caractérisées par la structure ou la composition comprenant des charges ou des agents de renforcement
B29C 70/06 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant uniquement des renforcements, p. ex. matières plastiques auto-renforçantes des renforcements fibreux uniquement
D03D 1/00 - Tissus conçus pour faire des articles particuliers
D04B 1/22 - Procédés de tricotage trame pour la production de tricots ou d'articles ne dépendant pas de l'emploi de machines spécialesTricots ou articles définis par de tels procédés spécialement conçus pour le tricotage d'articles de configuration particulière
D04B 21/20 - Procédés de tricotage chaîne pour la production de tricots ou articles qui ne dépendent pas de l'emploi de machines particulièresTricots ou articles définis par de tels procédés spécialement conçus pour le tricotage d'articles à configuration particulière
[Problem] To provide a hydrogen generating apparatus that efficiently generates hydrogen from ammonia, and a fuel cell system that generates power using the efficiently generated hydrogen. [Solution] A hydrogen generating apparatus (1) is provided with a plasma reactor (3), a high-voltage electrode (5), a grounding electrode (7), and a gas supply means (15) that supplies a gas containing ammonia to the plasma reactor. The high-voltage electrode (5) is configured with a hydrogen separation membrane (12) included therein. Under the conditions of room temperature and atmospheric pressure, the hydrogen separation membrane (12) of the high-voltage electrode (5) discharges electricity between the grounding electrode (7) and the hydrogen separation membrane with power supplied from a high-voltage pulse power supply (2), and hydrogen is generated by bringing into the plasma state the ammonia contained in the gas thus supplied.
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p. ex. de l'ammoniac
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
C01B 3/56 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification par contact avec des solidesRégénération des solides usés
H01M 8/06 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus
NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (Japon)
GIFU UNIVERSITY (Japon)
Inventeur(s)
Nishiyama Akira
Suzuki Fumiaki
Abrégé
Provided is a new cancer marker for testing the morbidity risk of cancer. The cancer marker of this invention is a prorenin receptor. The method for testing the morbidity risk of cancer of this invention is a method which measures the expression of prorenin receptors in a biological sample of a subject, and further includes, for example, a step in which the morbidity risk of cancer of the subject is tested by comparing the level of expression of prorenin receptors in the biological sample of the subject with a reference value. The reference value is the level of expression of prorenin receptors in the biological sample of healthy subjects or the level of expression of prorenin receptors in the biological samples of cancer patients. If the level of expression in the subject is higher than the level of expression in a healthy subject, is the same as the level of expression in the cancer patient, or is higher than the level of expression in the cancer patient, the subject is deemed to have a risk of dying from cancer.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
66.
PLURIPOTENT STEM CELL THAT INDUCES REPAIR AND REGENERATION AFTER MYOCARDIAL INFARCTION
The purpose of the present invention is to provide a new medical application using pluripotent stem cells (Muse cells) for regenerative medicine. The present invention provides a cell formulation for treating myocardial infarctions, especially severe, large-scale myocardial infarctions, and accompanying heart failure. Said cell formulation contains SSEA3-positive pluripotent stem cells isolated from either mesenchymal tissue from an organism or cultured mesenchymal cells. This cell formulation is based on the following myocardial-tissue regeneration mechanism: intravenous administration of Muse cells to subjects with the abovementioned disorders results in said Muse cells selectively accumulating in the damaged myocardial tissue and, within said tissue, differentiating into cardiac muscle.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
The purpose of the present invention is to provide a new medical application using pluripotent stem cells (Muse cells) for regenerative medicine. The present invention provides a cell formulation for treating myocardial infarctions, especially severe, large-scale myocardial infarctions, and accompanying heart failure. Said cell formulation contains SSEA3-positive pluripotent stem cells isolated from either mesenchymal tissue from an organism or cultured mesenchymal cells. This cell formulation is based on the following myocardial-tissue regeneration mechanism: intravenous administration of Muse cells to subjects with the abovementioned disorders results in said Muse cells selectively accumulating in the damaged myocardial tissue and, within said tissue, differentiating into cardiac muscle.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
[Problem] The present invention addresses the problem of providing a method for rapidly methylating sp3 carbon under conditions having a low [11C]CH3I concentration, which is applicable to the methylation of [11C]. [Solution] The method for methylating sp3 carbon according to the present invention is characterized by cross-coupling a boronic acid ester compound in which a carbon atom at an allyl position or a benzyl position has been esterified with boronic acid and methyl iodide in an aprotic polar solvent such as DMF under such a condition that a palladium complex represented by general formula Pd[PR1R2R3]2 (wherein at least one of three substituents R1, R2 and R3 is an alkyl group) and a base are present. It is preferred that the aprotic polar solvent contains water. Examples of the compounds represented by general formula Pd[PR1R2R3]2 include Pd[P(tert-C4H9)3]2 and others.
C07C 1/32 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir de composés renfermant des hétéro-atomes autres que l'oxygène ou les halogènes, ou en addition à ceux-ci
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
A diagnosis support system includes a diagnosis support computer that includes a model data acquisition unit configured to obtain a plurality of mandible model data, a contour model creation unit configured to create contour model data from the mandible model data, a contour database storage unit configured to construct a contour model database from the contour model data, a diagnosis image data receiving unit configured to receive an input of diagnosis image data of an examinee, an edge extraction unit configured to extract edge data from the diagnosis image data, a similar model searching unit configured to search contour model data based on the edge data, a position judgment unit and an image quality judgment unit configured to judge an imaging position and an image quality based on imaging information, respectively, and a diagnosis support information provision unit configured to provide diagnosis support information based on provider information.
A61B 6/14 - Applications ou adaptations à l'art dentaire
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
70.
METHOD FOR IDENTIFYING AND QUANTIFYING TYPES OF ANIMAL HAIR
KE'KEN TEXTILE TESTING & CERTIFICATION CENTER (Japon)
Inventeur(s)
Nishikawa, Kazuya
Yokogawa, Takashi
Ohno, Satoshi
Hayashi, Katsumasa
Matsunaga, Nobuyoshi
Motoyama, Aya
Abrégé
The present invention addresses the issue of providing a method which enables the identification and quantification of types of animal hair from a sample containing animal hair by directly analyzing protein which is the main component of animal hair, rather than using DNA which is present in small quantities. The present invention provides a method in which mass spectrometry of an animal hair sample is carried out, enabling, as a result of the analysis, the mass, mass/charge ratio (m/z), LC elution time for the mass/charge ratio, and a partial sequence useful as a marker to be identified for protein components such as keratin which are the main protein components of animal hair, and types of animal hair to be identified and quantified on the basis of these results.
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
C07K 5/00 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés
C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
G01N 33/483 - Analyse physique de matériau biologique
Provided is a medicinal composition for treating infarction, such as myocardial infarction and cerebral infarction, using a method that is different from conventional therapeutic methods with the use of a thrombolytic agent or balloon therapy. An autophagy enhancer such as hsa-miR-145 is used as the active ingredient of the medicinal composition for treating infarction. In particular, an autophagy enhancer such as hsa-miR-145 being in a liposomal form is used as the active ingredient of the medicinal composition for treating infarction.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
Provided are a gas treatment device and a gas treatment method which can reduce nitrogen oxides in gas which is to be treated, reliably and with low processing-costs. This gas treatment method for reducing nitrogen oxides in nitrogen oxide-containing gas which is to be treated is characterised by irradiating ultraviolet light from an ultraviolet light radiating lamp onto a mixed gas of a carrier gas and a raw material gas which can generate ammonia radicals, thus generating ammonia radicals, and then mixing the ammonia radicals into the gas which is to be treated, thus reducing the nitrogen oxides in the gas which is to be treated.
The present invention relates to the following: a complex compound which has an imidazo[1,5-a]pyridine derivative, characterized in being represented by general formula (I), as the ligand; a method for synthesizing the same; and the use of the complex compound. The complex compound is obtained by a simplified production method from readily available starting materials.
C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
H01L 51/50 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés pour l'émission de lumière, p.ex. diodes émettrices de lumière organiques (OLED) ou dispositifs émetteurs de lumière à base de polymères (PLED)
74.
HELMHOLTZ RESONANCE CONTAINER FOR VOLUME MEASUREMENT, VOLUME MEASUREMENT DEVICE, AND VOLUME MEASUREMENT METHOD
A Helmholtz resonance container (110) for enabling the volume of an object to be measured in a noncontact manner using Helmholtz resonance in a liquid comprises: a container (130) having a sealable opening (132); a neck (138) having a lower end communicating with a hollow portion inside the container (130) and an open upper end; and a cover member (140) provided at the upper end of the neck (138) and having an opening communicating with the inside of the neck (138). An edge of the opening (112) of the cover member (140) forms a reed (152) for generating sound and becomes thinner as approaching the opening. Sound is generated by the reed (152) by hitting a water current against the reed (152) from a water pipe (118), and in response to this sound, Helmholtz resonance is generated in the container (110). The volume of the object can be measured by a predetermined functional relation by putting the object in the container (130) and checking the peak frequency of the Helmholtz resonance.
Provided are a device (10) and a method for measuring the crispness of a food product. An item to be measured (22) comprising a porous food product is broken apart by causing the blade of a knife (14) to penetrate into the item. A vibration detector (18) attached to the knife (14) detects crack vibrations from cracks that form when the item to be measured (22) is broken apart. In a computer (20), the small crack vibrations of a predetermined vibration power or less that are included in the crack vibrations within an individual cracking duration time are extracted from the detected crack vibrations. Crispness is measured on the basis of the number of extracted small crack vibrations counted (number of cracks).
G01N 19/00 - Recherche sur les matériaux par des procédés mécaniques
G01N 29/14 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet utilisant des techniques d'émission acoustique
G01N 3/40 - Recherche de la dureté ou de la dureté au rebondissement
G01N 29/46 - Traitement du signal de réponse détecté par analyse spectrale, p. ex. par analyse de Fourier
A compound represented by formula (I) has an excellent noxious organism control activity. [R1 represents a C1-8 alkyl group or the like; W represents a halogen atom or the like; n represents an integer of 0 to 4; A represents a bicycic to tricyclic condensed aromatic hetero ring containing at least one nitrogen atom, or the like; and B represents a 5- to 6-membered aromatic hetero ring which is bound to a nitrogen atom in A.]
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A01N 43/40 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons
A01N 43/90 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant plusieurs hétérocycles déterminants condensés entre eux ou avec un système carbocyclique commun
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
The present invention provides a compound represented by general formula (1). In general formula (1): G represents a hexose-6-phosphate group; and L represents a divalent linker group.
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
Although competitive detection methods are generally considered to be effective as a simplified method of detecting sugar chains, such methods are unsuited to quantitative determination. Provided is a sugar chain detection method that resolves such issues encountered when using conventional techniques. The method for detecting sugar chains using a molecular probe that can bind specifically to the sugar chains comprises bringing into contact with a specimen a substance that labels the molecular probe using a photocrosslinking agent that can bind to the sugar chains, and then irradiating the specimen with light and crosslinking the sugar chains which have specifically binded to the molecular probes. A kit for detecting sugar chains contains (a) and (b) below. (a) A photocrosslinking agent and molecular probe that can bind to the sugar chains (b) A molecular probe that is labelled using a crosslinking agent that can bind to the sugar chains Provided are a screening method for substances that bind specifically to a sugar chain, and a kit therefor, and a disease testing method in which the sugar chain acts as a diagnostic marker, and a kit therefor.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
[Problem] To provide a canine madness vaccine which is higly safe, effective and inexpensive. [Solution] Provided are: a mutant canine madness virus (e.g., strain ERA-N273/394-G333 shown in fig. 2) which has at least the following mutations in a structural protein of a canine madness virus, i.e., the mutation of the amino acid reside at position-273 in N protein into an amino acid residue other than phenylalanine, the mutations of the amino acid reside at position-394 in N protein into an amino acid residue other than tyrosine, and the mutation of the amino acid residue at position-333 in G protein into an amino acid residue other than arginine or lysine; a canine madness vaccine preparation containing the mutant canine madness virus; and others. The introduction of the mutation of the amino acid residue at position-333 in G protein induces the attenuation of the virulence of a canine madness virus, and the introduction of the mutations of the amino acid residues at position-273 and position-394 in N protein induces the improvement in immunogenicity and safety of the canine madness virus. In addition, the introduction of the mutations of the amino acid residues at position-273 and position-394 in N protein enables the prevention of the increase in the virulence of the canine madness virus even when the mutation of the amino acid residue at position-194 in G protein into lysine occurs and, as a result, the possibility of the occurrence of reversion of pathogenicity of the canine madness virus caused by mutation can be reduced and the safety of the canine madness virus can be further improved.
The objective of the present invention is to provide: a uracil-requiring Moorella bacteria resulting from destroying the gene coding for orotidine-5-phosphate decarboxylase; and a transforming-gene-introduced Moorella bacteria resulting from introducing a transforming gene and a gene coding for orotidine-5-phosphate decarboxylase to the chromosome of the uracil-requiring Moorella bacteria. The objective is resolved by means of a uracil-requiring Moorella bacteria that results from destroying the gene coding for orotidine-5-phosphate decarboxylase in the chromosome of a Moorella bacteria, and that is characterized by belonging to the MTA-D-pF strain.
The objective of the present invention is to provide a primer set used in transformation imparting uracil-requiring properties by deleting or destroying the gene coding for orotidine-5-phosphate decarboxylase in a Moorella bacteria. The objective was resolved by means of a primer set that is used when producing a uracil-requiring strain of which the gene coding for orotidine-5-phosphate decarboxylase has been deleted or destroyed by means of homologous recombination in a Moorella bacteria, and that is characterized by being represented by sequence number 1 and sequence number 2, which amplify the upstream region neighboring the gene coding for orotidine-5-phosphate decarboxylase.
The endoscopic treatment instrument is equipped with a pliable flexible sheath, an operating wire inserted to be freely advancible and retractable in said flexible sheath, a basket provided on the distal end of said operating wire and configured from multiple elastic wires, and a clasp provided at the distal ends of said elastic wires to tie the multiple elastic wires together. The region of said basket of maximum diameter in the radial direction is located closer to the clasp than the midway point in the central axial direction between the proximal end of the basket and the clasp. Each of the multiple elastic wires has a helical shape that is wound in the same direction over the entire length thereof and the winding pitch becomes gradually smaller when moving from the distal end of the operating wire towards the clasp.
The diagnosis assistance system (1) is equipped with a diagnosis assistance computer (3) comprising: a model data-acquiring means (14) for acquiring multiple mandible model data (9); a contour model-generating means (16) for generating contour model data (15) from the mandible model data; a contour database storage means (20) for building a contour model database (19) from the contour model data (15), etc.; a diagnostic image data-receiving means (21) for receiving input of a subject's diagnostic image data (6); an edge-extracting means (23) for extracting edge data (22) from the diagnostic image data (6); a similar model-retrieving means (24) for retrieving similar contour model data (15) on the basis of the edge data (22); a position-assessing means (25) and image quality-assessing means (26) for assessing imaging position, etc. and image quality on the basis of imaging information (17); and a diagnosis-assisting information-providing means (27) for providing diagnosis-assisting information (7) on the basis of donor information (18).
A61B 6/14 - Applications ou adaptations à l'art dentaire
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
84.
COMPOUND HAVING HEPTAMETHINE STRUCTURE, SENSITIZING DYE AND PHOTOELECTRIC CONVERSION ELEMENT
Provided are: a compound which has heptamethine structure and which is to be used as a sensitizing dye in a photoelectric conversion element, said compound being represented by formula (1); and a photoelectric conversion element which includes the compound as the sensitizing dye and which can resolve the problems of the prior art. In formula (1), R1 and R2 are each a hydrogen atom, alkyl or aryl; R3 to R6 are each C1-12 alkyl; X is a halogen atom; Y is a monovalent anion; when R3 to R6 are each C1-5 alkyl, Z is alkyl, alkoxy or aryl, while when R3 to R6 are each C6-5 alkyl, Z is a hydrogen atom, alkyl, alkoxy or aryl; and m and n are each an integer of 1 to 12.
C07D 209/14 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
C09B 23/00 - Colorants méthiniques ou polyméthiniques, p. ex. du type cyanine
H01L 31/04 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails adaptés comme dispositifs de conversion photovoltaïque [PV]
H01M 14/00 - Générateurs électrochimiques de courant ou de tension non prévus dans les groupes Leur fabrication
85.
LATERAL FACE INSTALLATION-TYPE FORCE SENSE DISPLAY INTERFACE
A force sense display interface comprises: haptic finger bases (16), further comprising a plurality of haptic fingers (21-25) which are capable of tracking the motion of the fingers (Ya) of the hands (Ha) of an operator (H); arm mechanisms (110) which allow spatial motion of the haptic finger bases (16); and controllers (200A, 200B) which control the arm mechanisms (110) in linkage with the position and attitude of the hands, and which control the haptic fingers (21-25) in linkage with the movements of the fingers (Ya), of the operator (H). The force sense display interface further comprises finger holders (26) for attaching the haptic fingers (21-25) on the fingers of the operator (H) in a state wherein the haptic finger bases (16) are distanced from the backs of the hands (Ha) of the operator (H) so as to be opposite the backs of the hands (Ha) thereof.
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
B25J 3/00 - Manipulateurs de type à commande asservie, c.-à-d. manipulateurs dans lesquels l'unité de commande et l'unité commandée exécutent des mouvements correspondants dans l'espace
B25J 13/02 - Moyens de commande à préhension manuelle
A finger motor (16) for driving a finger is linked to a worm reduction mechanism (17). A worm wheel (19), which is the output gear of the worm reduction mechanism (17), rotates, so that a metacarpophalangeal joint (15) bends and extends. The metacarpophalangeal joint (15) is linked through two link mechanisms consisting of a first driving link (21) and a second driving link (23) to a proximal interphalangeal joint (20) and a distal interphalangeal joint (22). This allows the proximal interphalangeal joint (20) and the distal interphalangeal joint (22) to bend and extend in conjunction with the bending and extending operations of the metacarpophalangeal joint (15).
Provided are a device (10) and a method for measuring the crispness of a food product. An item to be measured (22) comprising a porous food product is broken apart by causing the blade of a knife (14) to penetrate into the item. A vibration detector (18) attached to the knife (14) detects crack vibrations from cracks that form when the item to be measured (22) is broken apart. In a computer (20), the small crack vibrations of a predetermined vibration power or less that are included in the crack vibrations within an individual cracking duration time are extracted from the detected crack vibrations. Crispness is measured on the basis of the number of extracted small crack vibrations counted (number of cracks).
G01N 3/30 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique en appliquant une force unique et brève
A01N 47/18 - Dérivés de l'acide carbamique, c.-à-d. contenant le groupe —O—CO—NLeurs thio-analogues contenant un groupe —O—CO—N, ou un de ses thio-analogues, lié directement à un hétérocycle ou à un cycle cycloaliphatique
A01N 47/36 - Urées ou thiourées contenant les groupes N—CO—N ou N—CS—N contenant le groupe N—CO—N lié directement à au moins un hétérocycleLeurs thio-analogues
C07D 277/20 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 277/32 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
89.
HYDROGEN CONTENT RATIO ACQUIRING APPARATUS AND HYDROGEN CONTENT RATIO ACQUIRING METHOD
Disclosed is a hydrogen content ratio acquiring apparatus (1), wherein the values of a predetermined parameter group and reference information, which relates the content ratio of SiH contained in a silicon film to the content ratio of SiH2 contained in the silicon film, are previously generated and stored. A measured spectrum of the silicon film on a glass substrate (9) is obtained by measuring the silicon film by means of a spectroscopic ellipsometer (3), and on the basis of the measured spectrum, the values of the parameter group are obtained using a computer (6). Then, on the basis of the parameter group values and the reference information, the value of the SiH content ratio and that of the SiH2 content ratio are accurately obtained.
G01N 21/27 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
90.
FOLDING METHOD AND FOLDING SYSTEM USING PRESS BRAKE
A final target press distance of an upper die against a workpiece can be calculated from a single folding. An upper die is forced into a V-shaped groove by a set press distance (St1) corresponding to a set finished angle (θ1) that is set so as to be larger than a specific finished angle (θF) of a workpiece from which a load applied thereto is removed when the workpiece is brought into contact with slopes of the V-shaped groove, and a finished angle (θM) of the workpiece is measured. A target press distance (StT) is calculated such that an inclination (f1) of a first straight line and an inclination (f2) of a second straight line satisfy a predetermined relationship in an St-θ graph indicating the relationship between a press distance (St) and a finished angle (θ), where the first straight line passes through a measuring point that is defined by the measured finished angle (θM) and the set press distance (St1) and an inflection point that is defined by the specific finished angle (θF) and a specific press distance (StF) corresponding to the specific finished angle (θF), and where the second straight line passes through the inflection point and a machining point that is defined by the target press distance (StT) corresponding to a target finished angle (θT).
Provided are novel imino derivatives serving as insecticidal compounds which exhibit excellent characteristics such as persistent effect and wide spectrum. The inimo derivatives are represented by general formula (A) [wherein Ar is a heterocyclic group which may have a substituent on the ring; X is a sulfur atom, CH2, or NR; R is a hydrogen atom or alkyl; Ya is selected from among C(=S)NR1R2, C(=S)SR3, C(=O)SR4, C(=S)OR4, SO2Zα and OZβ; and R1 to R4, Zα and Zβ are each a hydrogen atom or a prescribed substituent.]
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
92.
NEURAMINIC ACID DERIVATIVE, SIALIDASE ACTIVITY INHIBITOR AND ANTIINFLUENZA DRUG
Provided are a neuraminic acid derivative, which selectively inhibits virus sialidase activity but little inhibits human sialidase activity, a sialidase activity inhibitor, and an antiinfluenza drug. The aforesaid neuraminic acid derivative is characterized by comprising a compound represented by chemical formula (1), a pharmaceutically acceptable salt thereof, a hydrate of the same, a solvate of the same or a prodrug of the same. In chemical formula (1), R1 and R2 represent hydrogen, an optionally branched C1-8 alkyl group or an optionally branched C1-8 cycloalkyl group; and R3 represents hydrogen or fluorine.
C07D 309/28 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
93.
AROMATIC COMPOUND, MODIFICATION CARRIER THAT USES SAME AND IS USED FOR SYNTHESIZING AN OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE, AND OLIGONUCLEOTIDE CONSTRUCT
Provided is an oligonucleotide derivative, the 3′ end of which is chemically modified with two skeletons selected from among benzene skeletons and pyridine skeletons. Said oligonucleotide derivative can be easily synthesized in a small number of steps. Also provided is an aromatic compound that serves as a precursor for preparing a modification carrier for synthesizing the oligonucleotide derivative. The oligonucleotide derivative and a provided oligonucleotide construct have good cell membrane permeability and excellent nuclease resistance. The aforementioned modification carrier is characterized in that the carrier is chemically modified, via a linker, with the unit represented by structural formula (a) (in which R1 through R6 each independently represent hydrogen or a non-hydrogen substituent, Z1 and Z2 each independently represent CH or nitrogen, and X represents oxygen or sulfur).
C07C 275/24 - Dérivés d'urée, c.-à-d. composés contenant l'un des groupes les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes urée liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant des cycles aromatiques à six chaînons
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07C 335/12 - Dérivés de thiourée ayant des atomes d'azote de groupes thiourée liés à des atomes de carbone acycliques d'un squelette carboné non saturé le squelette carboné contenant des cycles aromatiques à six chaînons
C07F 9/6558 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant au moins deux hétérocycles différents ou différemment substitués ni condensés entre eux ni condensés avec un carbocycle commun ou un système carbocyclique commun
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
94.
METHOD FOR DETECTION OF GLYCOSAMINOGLYCAN, AND MOLECULAR PROBE FOR USE IN THE METHOD
Disclosed are: a molecular probe which can overcome the disadvantages of the conventional techniques; and a method for detecting glycosaminoglycan using the molecular probe. Specifically disclosed are: a method for detecting glycosaminoglycan, which comprises bringing a molecular probe that comprises a substance capable of binding to glycosaminoglycan specifically and having a free thiol group into contact with a sample, adding N-(9-acridinyl)maleimide to the resulting mixture to generate a fluorescence, and measuring the fluorescence; a glycosaminoglycan detection kit which comprises a molecular probe that comprises a substance capable of binding to glycosaminoglycan specifically and having a free thiol group and N-(9-acridinyl)maleimide; a method for screening for a substance capable of binding to glycosaminoglycan specifically, and a kit for use in the method; and a method for diagnosing a disease for which glycosaminoglycan can be used as a diagnosis marker, and a kit, a molecular probe and a peptide for use in the method.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
National University Corporation Nagoya University (Japon)
Inventeur(s)
Akao Yukihiro
Takenishi Soichiro
Naoe Tomoki
Abrégé
Provided is a composition comprising one or more kinds of RNA-enclosing carriers, said carriers being selected from among a monocyte, a macrophage and a shedding microvesicle originating in these cells. The RNA-enclosing carrier(s) in the aforesaid composition can maintain the RNA in a stable state in vivo.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Disclosed is a compound which has a high affinity for a CD22 molecule in a B cell and can enhance an immune response to thereby exhibit activities including an activity of enhancing the proliferation of B cells and an activity of increasing the resistance against infectious diseases such as virus-mediated diseases. The compound is a sialic acid derivative represented by chemical formula (1) (wherein R1 and R2 independently represent an aromatic hydrocarbon group which may have a substituent) or a prodrug thereof, or a pharmaceutically acceptable salt or hydrate of the derivative or prodrug.
A61K 31/7012 - Composés ayant un groupe carboxyle libre ou estérifié, lié directement ou par une chaîne carbonée, à un atome de carbone du radical saccharide, p. ex. acide glucuronique, acide neuraminique
Provided is a novel compound which is capable of inhibiting the formation of an infectious prion protein via binding to a normal prion protein. Specifically provided is a compound represented by formula (1). In formula (1), X represents a carbon atom or a nitrogen atom; R1 and R2 may be either the same or different and represent a hydrogen atom, an oxygen atom, a halogen atom, a hydroxy group, a mercapto group, a cyano group, a carboxy group, a carbamoyl group, an alkoxycarbonyl group, an acyloxy group, an acyl group, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted amino group, etc.; and R3 to R6 may be either the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, etc., provided that at least one of R1 and R2 represents a group other than hydrogen atom.
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 295/14 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
98.
THIAZOLE DERIVATIVE AND PROCESS FOR PRODUCING SAME
A thiazole derivative is produced from easily available starting materials by a simplified process. The process is for producing a novel thiazole derivative represented by general formula (I), and is characterized by adding a strong base to a thioamide represented by general formula (II) and reacting the mixture with a thioformamide represented by general formula (III).
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
Provided is an upper limb motion assist device capable of detecting motions in the directions of six axes by an inexpensive configuration. The upper limb motion assist device is provided with: a first detection means (52, 54, 56, 58, 60, 62) which is capable of detecting force that causes the movement of an operation portion (32) which a person to be assisted can grip and operate in each of an X-axis direction along the operation portion (32), a Y-axis direction orthogonal to the X-axis, and a Z-axis direction orthogonal to the X-Y axes; a second detection means (66, 68, 70, 72) which is disposed apart from the first detection means (52, 54, 56, 58, 60, 62) in the X-axis direction and is capable of detecting force that causes the movements of the operation portion (32) in the Y-axis direction and the Z-axis direction; a third detection means (76, 78) which is capable of detecting the rotation of the operation portion (32) about the X-axis or force that causes said rotation; and a control means (14) which is connected to the first to third detection means (52, 54, 56, 58, 60, 62, 66, 68, 70, 72, 76, 78), wherein the drive of a multijoint arm is controlled on the basis of detection signals inputted from the first to third detection means (52, 54, 56, 58, 60, 62, 66, 68, 70, 72, 76, 78).
B25J 13/02 - Moyens de commande à préhension manuelle
A61H 1/02 - Appareils d'exercice extenseurs ou de ployage
B25J 13/08 - Commandes pour manipulateurs au moyens de dispositifs sensibles, p. ex. à la vue ou au toucher
G01L 5/16 - Appareils ou procédés pour la mesure des forces, du travail, de la puissance mécanique ou du couple, spécialement adaptés à des fins spécifiques pour la mesure de plusieurs composantes de la force
Disclosed is a wearable motion support device which can support the motion of a user appropriately by enhancing the detection accuracy of the body motion of the user. A wearable motion support unit (SU1) comprises a first support member (10) which is fitted to the proximal body part (A2) of a joint (A1), a second support member (12) which is coupled with the first support member (10) in such a manner that the posture can be changed and is fitted to the distal body part (A3) of the joint (A1), an outer member (80) arranged on the second support member (12), and an inner member (81) which is arranged on the distal body part (A3) side of the outer member (80) in such a manner as to approach the outer member (80) or to separate therefrom and is fitted to the distal body part (A3). On the inner circumferential surface of the outer member (80), a pressure sensor which detects the magnitude of a pushing force at the time when the inner member (81) pushes the outer member (80) by the movement of the distal body part (A3) is arranged.